The stock of Werewolf Therapeutics Inc (HOWL) has gone down by -12.33% for the week, with a 21.74% rise in the past month and a 18.52% rise in the past quarter. The volatility ratio for the week is 8.53%, and the volatility levels for the past 30 days are 12.07% for HOWL. The simple moving average for the last 20 days is -11.58% for HOWL stock, with a simple moving average of -43.62% for the last 200 days.
Is It Worth Investing in Werewolf Therapeutics Inc (NASDAQ: HOWL) Right Now?
Company’s 36-month beta value is 0.40.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HOWL is 32.07M, and currently, short sellers hold a 2.42% ratio of that floaft. The average trading volume of HOWL on November 08, 2024 was 595.22K shares.
HOWL) stock’s latest price update
Werewolf Therapeutics Inc (NASDAQ: HOWL)’s stock price has plunge by -8.20relation to previous closing price of 2.44. Nevertheless, the company has seen a -12.33% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-07 that – Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals –
Analysts’ Opinion of HOWL
Many brokerage firms have already submitted their reports for HOWL stocks, with JMP Securities repeating the rating for HOWL by listing it as a “Mkt Outperform.” The predicted price for HOWL in the upcoming period, according to JMP Securities is $12 based on the research report published on April 03, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see HOWL reach a price target of $9. The rating they have provided for HOWL stocks is “Outperform” according to the report published on August 24th, 2023.
Jefferies gave a rating of “Buy” to HOWL, setting the target price at $12 in the report published on June 06th of the previous year.
HOWL Trading at -1.33% from the 50-Day Moving Average
After a stumble in the market that brought HOWL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.66% of loss for the given period.
Volatility was left at 12.07%, however, over the last 30 days, the volatility rate increased by 8.53%, as shares surge +23.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.75% lower at present.
During the last 5 trading sessions, HOWL fell by -12.33%, which changed the moving average for the period of 200-days by -45.63% in comparison to the 20-day moving average, which settled at $2.53. In addition, Werewolf Therapeutics Inc saw -41.97% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HOWL
Current profitability levels for the company are sitting at:
- -6.28 for the present operating margin
- 0.8 for the gross margin
The net margin for Werewolf Therapeutics Inc stands at -5.79. The total capital return value is set at -0.41. Equity return is now at value -48.27, with -31.70 for asset returns.
Based on Werewolf Therapeutics Inc (HOWL), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -1.56. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -13.62.
Currently, EBITDA for the company is -38.74 million with net debt to EBITDA at 1.73. When we switch over and look at the enterprise to sales, we see a ratio of -0.08. The receivables turnover for the company is 17.03for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.13.
Conclusion
In a nutshell, Werewolf Therapeutics Inc (HOWL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
